List of Excipients in Branded Drug SECUADO
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Noven Therapeutics LLC | SECUADO | asenapine | 68968-0172 | BUTYLATED HYDROXYTOLUENE | 2033-09-22 |
| Noven Therapeutics LLC | SECUADO | asenapine | 68968-0172 | ISOPROPYL PALMITATE | 2033-09-22 |
| Noven Therapeutics LLC | SECUADO | asenapine | 68968-0172 | MINERAL OIL | 2033-09-22 |
| Noven Therapeutics LLC | SECUADO | asenapine | 68968-0172 | POLYISOBUTYLENE | 2033-09-22 |
| Noven Therapeutics LLC | SECUADO | asenapine | 68968-0172 | SODIUM ACETATE ANHYDROUS | 2033-09-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
SECUADO Excipient Strategy and Commercial Opportunities in Transdermal Asenapine
Secuado is a once-daily asenapine transdermal system for schizophrenia in adults. Its commercial differentiation comes from drug-in-adhesive delivery, which avoids oral administration and provides continuous systemic exposure. The core excipient opportunity is not a conventional tablet formulation. It is a controlled adhesive matrix requiring simultaneous optimization of drug loading, skin permeation, adhesion, crystallization control, release performance, manufacturing yield, and patient wear time.
Secuado was approved by the U.S. Food and Drug Administration on September 20, 2019, in three strengths delivering 3.8 mg, 5.7 mg, or 7.6 mg of asenapine over 24 hours. The product was developed by Noven Pharmaceuticals and marketed through the Allergan and later Teva commercial organizations. [1]
What is Secuado and how does its excipient system work?
Secuado is a drug-in-adhesive transdermal patch. The active pharmaceutical ingredient is asenapine maleate, an atypical antipsychotic previously marketed as Saphris sublingual tablets.
The patch contains a pressure-sensitive adhesive matrix that holds the drug and controls contact with the skin. The system also includes a backing layer and a removable release liner. The excipient design must support several functions at once:
| Functional layer | Primary role | Commercial risk |
|---|---|---|
| Drug-in-adhesive matrix | Holds and releases asenapine | Drug crystallization, dose uniformity, release variability |
| Pressure-sensitive adhesive | Maintains skin contact | Edge lift, irritation, poor adhesion |
| Backing layer | Protects the matrix | Moisture ingress and mechanical failure |
| Release liner | Protects the adhesive before use | Incomplete release or handling defects |
| Packaging system | Protects the patch during storage | Adhesive aging and stability loss |
The product is applied once daily to the upper torso, upper arm, back, or hip. The label instructs patients to wear one patch continuously for 24 hours and replace it at approximately the same time each day. [1]
What excipients are used in Secuado?
The Secuado label identifies a transdermal adhesive system containing polymeric adhesive components, tackifying materials, and mineral oil, together with backing and release-liner materials. The listed inactive materials include polyisobutylene, mineral oil, styrene-isoprene-styrene block copolymer, and a hydrogenated rosin ester. [1]
The excipient strategy can be divided into four technical groups.
Polyisobutylene and related adhesive polymers
Polyisobutylene provides pressure-sensitive adhesion and contributes to the matrix structure. It is useful for maintaining contact with the skin over a full day without requiring a separate liquid reservoir.
Key formulation variables include:
- Polymer molecular weight
- Polymer blend ratio
- Cohesive strength
- Tack and peel adhesion
- Drug-polymer compatibility
- Residual solvent content, where solvent processing is used
Polyisobutylene systems are commercially attractive because they are established in transdermal and topical products. The principal barrier is not basic availability. It is matching the reference product's mechanical, adhesive, and drug-release profile.
Styrene-isoprene-styrene block copolymer
Styrene-isoprene-styrene is an elastomeric block copolymer that can improve matrix cohesion and flexibility. It can help balance tack with resistance to cold flow, residue, and edge ooze.
The polymer also creates formulation latitude for tuning:
- Peel strength
- Shear resistance
- Flexibility during movement
- Adhesive residue
- Drug diffusion through the matrix
Substitution with another elastomer may be technically feasible but creates regulatory and performance risk. A different polymer can change drug activity, diffusion pathways, skin partitioning, and patch wear.
Mineral oil
Mineral oil functions as a softener and processing aid. It can reduce matrix stiffness and improve flexibility. Excessive mineral oil can reduce cohesive strength, increase residue, alter drug diffusivity, and impair dimensional stability.
For a generic or follow-on developer, mineral oil concentration is a likely critical material attribute. Small changes can affect both adhesion and drug delivery.
Hydrogenated rosin ester
Hydrogenated rosin ester is a tackifier. It increases initial adhesion and may improve contact with the skin across different body sites.
Tackifier selection requires control of:
- Acid value and softening point
- Oxidative stability
- Skin compatibility
- Color and odor
- Lot-to-lot variability
- Interaction with asenapine and other polymers
A hydrogenated tackifier is commercially useful because it can provide adhesion without relying on aggressive acrylic chemistry. Its impurity profile and supplier consistency remain important for long-term stability.
What is the commercial advantage of Secuado's excipient strategy?
Secuado's principal product advantage is a route-of-administration change rather than a new pharmacological mechanism. The patch can provide an option for patients who have difficulty swallowing, resist oral medication, or need a delivery format that does not require daily ingestion.
The FDA label reports that Secuado produces dose-proportional exposure across the 3.8 mg, 5.7 mg, and 7.6 mg strengths. It also reports that steady-state exposure is reached after approximately three days of daily patch application. [1]
The commercial value of the excipient system is tied to four attributes:
- Continuous delivery over 24 hours.
- Reduced dependence on gastrointestinal administration.
- Visible and removable dosing.
- A differentiated product format in the antipsychotic market.
The disadvantages are also formulation-driven. The product requires skin application, can cause application-site reactions, and has adhesion requirements that oral products do not have. The label identifies application-site erythema, application-site pruritus, application-site irritation, and application-site pain among reported adverse reactions. [1]
What formulation patents protect Secuado?
Secuado's formulation protection is expected to center on transdermal asenapine systems, adhesive matrices, drug loading, delivery rates, and manufacturing processes rather than on the active molecule itself.
Asenapine's original composition-of-matter protection is separate from the transdermal product. Secuado entered the market more than a decade after Saphris, so the commercial patent value shifted toward:
- Transdermal delivery of asenapine
- Specific adhesive compositions
- Patch architecture
- Release characteristics
- Dosing strengths
- Manufacturing and packaging controls
- Methods of treating schizophrenia with the patch
The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity. Product-specific Orange Book entries should be reviewed by strength and dosage form because the listed claims can differ from patents associated with oral asenapine. [2]
Are method-of-use patents important for Secuado?
Method-of-use patents can protect treatment with transdermal asenapine in schizophrenia or related patient populations. Their practical value depends on claim scope, statutory expiration, enforceability, and whether a generic applicant can use a Section VIII statement or must make a Paragraph IV certification.
Method-of-use claims are more difficult to enforce against a generic if the generic label omits the patented use. They are stronger when the protected use is inseparable from the approved indication or when the product's labeling induces the patented method.
When did Secuado lose FDA exclusivity?
Secuado received three-year regulatory exclusivity associated with the approval of a new dosage form supported by new clinical investigations. That exclusivity period generally ran from the September 2019 approval date and did not extend to the full patent term. [1, 3]
The practical entry date for a generic depends on:
- The expiration of listed patents
- Any pediatric exclusivity attached to those patents
- Paragraph IV litigation
- Court-imposed stays
- The approval status of an ANDA
- Whether the applicant can establish pharmaceutical equivalence and bioequivalence for the patch
Regulatory exclusivity and patent exclusivity must be analyzed separately. The end of the three-year exclusivity period did not automatically authorize generic entry.
What Paragraph IV challenges and generic entry risks exist?
A generic Secuado applicant would likely use the abbreviated new drug application pathway under Section 505(j), but transdermal systems impose greater development complexity than conventional tablets.
A Paragraph IV strategy could challenge:
- The validity of transdermal asenapine patents
- Infringement of adhesive-matrix claims
- The scope of formulation claims
- The enforceability of method-of-use claims
- The patentability of specific patch strengths or release profiles
The principal generic risks are technical rather than limited to patent validity. A follow-on product must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements applicable to transdermal systems. The applicant must also address adhesion, irritation, residual drug, peel performance, release rate, and stability.
A non-infringing generic design could alter the adhesive polymer, tackifier, plasticizer, backing, or release liner. That approach reduces direct formulation overlap but increases bioequivalence and product-performance risk.
How strong is the Secuado patent estate?
The estate is potentially stronger than a conventional dosage-form estate because transdermal claims can cover multiple layers of the product.
| Patent category | Relevance to Secuado | Likely design-around difficulty |
|---|---|---|
| Asenapine composition patents | Low for a mature active ingredient | Usually low after expiration |
| Transdermal delivery claims | High | Moderate to high |
| Adhesive-matrix composition claims | High | Moderate |
| Patch construction claims | Moderate to high | Moderate |
| Manufacturing-process claims | Moderate | Variable |
| Method-of-use claims | Moderate | Often dependent on labeling |
| Packaging and stability claims | Low to moderate | Usually manageable |
The strongest commercial claims are those that connect a specific adhesive composition with a defined asenapine delivery profile. Broad claims covering any asenapine patch are more vulnerable to prior-art challenges than claims requiring a defined polymer combination, drug concentration, or flux range.
What manufacturing and excipient barriers affect generic Secuado development?
The key manufacturing barrier is reproducible coating of a low-dose active ingredient into a large-area adhesive matrix. Critical process parameters can include:
- Mixing temperature and time
- Drug dispersion
- Polymer dissolution
- Coating weight
- Drying temperature
- Residual solvent
- Lamination pressure
- Slitting and die-cutting
- Pouch sealing
- In-process content uniformity
A small patch-to-patch variation can affect dose delivery because the system operates through controlled skin flux rather than immediate disintegration.
Manufacturers also need qualified sources for pharmaceutical-grade adhesive polymers, tackifiers, mineral oil, backing films, and release liners. A change in supplier can alter molecular-weight distribution, tack, extractables, residual impurities, or coating behavior. Such changes may require comparability testing and regulatory documentation.
What commercial opportunities exist in Secuado excipients?
The largest opportunities are in formulation development, excipient supply, process equipment, and analytical testing.
Excipient supply
Suppliers can target:
- Medical-grade polyisobutylene
- Styrene-isoprene-styrene polymers
- Hydrogenated rosin esters
- Controlled-purity mineral oils
- Low-extractable backing films
- Silicone-coated release liners
The strongest value proposition is consistent lot performance rather than simple commodity pricing.
Generic and authorized-generic development
A developer can pursue:
- A direct generic patch
- A non-infringing adhesive matrix
- A different patch size at equivalent delivery strength
- A private-label or regional transdermal asenapine product
- Contract development for a specialty pharmaceutical company
The main investment is in comparative adhesion, in vitro release, skin permeation, adhesion scoring, irritation studies, and clinical or pharmacokinetic bridging where required.
Excipient and process licensing
Licensing opportunities may involve:
- Proprietary pressure-sensitive adhesive platforms
- Hot-melt coating processes
- Solvent-free manufacturing
- Anti-crystallization technology
- Controlled drug dispersion
- Low-irritation tackifier systems
- Moisture-barrier packaging
A platform license is more defensible when it covers both composition and manufacturing know-how. A single substitute excipient generally has weaker commercial leverage unless it improves a measurable product attribute.
Specialty distribution and patient support
Transdermal antipsychotic therapy may support specialty-pharmacy services, adherence monitoring, application training, and caregiver programs. These services can reduce patch detachment and improper application, which directly affect real-world exposure.
How does Secuado compare with oral asenapine and long-acting injectables?
| Attribute | Secuado | Oral asenapine | Long-acting injectable antipsychotic |
|---|---|---|---|
| Administration | Daily patch | Daily sublingual tablet | Infrequent injection |
| Main excipient challenge | Adhesion and skin delivery | Taste, disintegration, oral exposure | Suspension or depot release |
| Visibility of dosing | High | Low | High |
| Gastrointestinal dependence | Avoided | Present to a greater extent | Avoided |
| Administration burden | Daily self-application | Daily dosing | Clinic visit |
| Generic complexity | High | Moderate | High |
| Biosimilar pathway | Not applicable | Not applicable | Not applicable |
Secuado does not create biosimilar exposure. It is a small-molecule drug-device combination product. Competitive threats come from oral generics, other transdermal products, and long-acting injectable antipsychotics.
What is the FDA regulatory status and Orange Book position of Secuado?
Secuado is an FDA-approved prescription drug delivered through a transdermal system. Its regulatory status is distinct from a biologic and does not involve a biosimilar pathway. [1]
The Orange Book identifies approved drug products and relevant patent and exclusivity information. Secuado should be assessed under the dosage-form and route entries for asenapine transdermal systems, not only under the older oral asenapine listings. [2]
For commercial diligence, the relevant questions are:
- Whether an ANDA has been submitted or approved
- Whether any Paragraph IV notice has been served
- Whether listed patents remain in force
- Whether a 30-month stay has been triggered
- Whether settlement terms permit an early launch
- Whether FDA has accepted the proposed generic's product-specific guidance pathway
Public company disclosures from Allergan and Teva have not established a separately reported Secuado revenue line. Revenue exposure therefore must be modeled from prescription volume, net price, payer coverage, and the product's share of the asenapine franchise rather than from a standalone reported figure. [4, 5]
Key Takeaways
- Secuado is a once-daily asenapine drug-in-adhesive transdermal system.
- Its principal excipient system uses pressure-sensitive adhesive polymers, mineral oil, and a hydrogenated rosin ester.
- The main formulation risks are crystallization, adhesion failure, skin irritation, drug-content uniformity, and coating variability.
- The product received FDA approval in September 2019 and had three-year regulatory exclusivity associated with its new dosage form.
- Generic entry depends on both Orange Book patents and FDA requirements for transdermal bioequivalence.
- A non-infringing generic can modify the adhesive system, but those changes create material performance and regulatory risks.
- Commercial opportunities exist in excipient supply, adhesive-platform licensing, generic development, coating technology, analytical testing, and adherence support.
- Secuado has no biosimilar pathway because it is a small-molecule drug-device combination product.
Frequently Asked Questions
Is Secuado a tablet or a patch?
Secuado is a once-daily transdermal patch that delivers asenapine through the skin over approximately 24 hours.
Which excipients are most important in Secuado?
The most important excipient classes are polyisobutylene, styrene-isoprene-styrene block copolymer, mineral oil, and hydrogenated rosin ester. These materials control adhesion, flexibility, matrix cohesion, and drug release.
Can a generic Secuado use different excipients?
Yes. A generic applicant can use a different excipient system if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, adhesion, safety, quality, and applicable patent constraints.
Does Secuado require a biosimilar application?
No. Secuado contains the small-molecule drug asenapine and is not regulated through the biosimilar pathway.
What is the largest technical barrier to a generic Secuado?
The largest barrier is reproducing the reference patch's combined drug-release and adhesion performance while maintaining content uniformity, skin tolerability, stability, and manufacturability.
References
- U.S. Food and Drug Administration. (2019). Secuado (asenapine) transdermal system prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2019). New drug application approval letter for Secuado.
- Allergan plc. (2020). Annual report.
- Teva Pharmaceutical Industries Ltd. (2023). Annual report.
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Deeper Knowledge, Faster
- Analyze global market entry opportunities
- Identify first generic entrants
- Obtain formulation and manufacturing information